Investorideas.com - Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX), Update on LibiGel® (testosterone gel) for the treatment of female sexual dysfunction and its Pancreatic Cancer Vaccine
Stephen M. Simes, President and CEO Discusses LibiGel (testosterone gel) in Phase III and GVAX Pancreas Vaccine in Phase II
November 2, 2010 - (Investorideas.com newswire, www.biotechindustrystocks.com)
www.InvestorIdeas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, presents the second in a series of Q&A interviews with BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
The first introductory Q&A can be found here:
http://www.investorideas.com/CO/BPAX/news/9211.asp
In this follow up, Stephen M. Simes, president and chief executive officer of BioSante Pharmaceuticals discusses recent developments with its lead product in Phase III, LibiGel (testosterone gel) in addition to GVAX Pancreas Vaccine in Phase 2.
Q: Investorideas.com
Your company just recently announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events by its independent Data Monitoring Committee (DMC). Can you give investors insight into the study, the subjects and the type of data collected?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Yes. We currently are conducting three Phase III LibiGel clinical studies, one of which is a very important cardiovascular events and breast cancer safety study to which you refer. We now have enrolled over 2,500 women into this study and to date the safety of LibiGel looks excellent. The rate of cardiovascular events that have been reported in the study is significantly lower than was predicted for this population of women, and the rate of breast cancer reported is close to predicted. Our objective is to show the safety of LibiGel in the treatment of female sexual dysfunction for which there is no FDA approved product today. We believe we are doing that.
Q: Investorideas.com
According to your press release, A new drug application (NDA) can be submitted after an average of 12 months of exposure with subjects followed for five years in total, including after NDA submission and potential FDA approval. BioSante’s objective is to submit the LibiGel NDA in 2011. The average time for FDA approval is six months to a year. Once approved by FDA, the drug becomes available for physicians to prescribe for patients- so the company is looking at 2012 for LibiGel to be available?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Our objective is to submit the new drug application (NDA) in 2011 for a potential approval and launch in 2012. We belive LibiGel will be the first product to enter this market, notwithstanding the fact that Viagra was approved for men over 12 years ago. The time for women to have a product to trat their sexual issues has come!
Q: Investorideas.com
You recently stated , “With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD”- for investors looking at potential revenue for this product , what does this represent for the company?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
The forecast for the size of the potential market for female sexual dysfunction products varies from $2 billion up to $5 billion. The market for erectile dysfunction products like Viagra is over $2 billion just in the U.S. We believe LibiGel alone has the potential to be a $1 billion per year product.
Q: Investorideas.com
In a recent article on Seeking Alpha, discussing pancreatic cancer, your company is featured in the section “Select Pancreatic Products in Active Clinical Development”. Can you give us an overview and update on the GVAX Pancreas Vaccine, Phase 2.
Article source for reference:
http://seekingalpha.com/article/232174-amgen-celgene-and-novartis-in-the-fight-against-pancreatic-cancer?source=yahoo
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We have a full pipeline of cancer vaccines in clinic al trials. In fact there are 12 ongoing clinical trials in pancreatic cancer and breast cancer among other cancer types. Cancer vaccines represent the next wave in potential therapies for cancer patients and we hope to contribute to that wave. Data to date have been excellent.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Or the company website www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech/Pharma Stocks portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech/pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (three thousand per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Forward-Looking Statements
This news release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as “will,” “potential,” “could,” “would,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For info about BioSante Pharmaceuticals, Inc
Contact:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com
Tuesday, November 2, 2010
Investorideas.com - Biotech Stocks Update; UV Flu Technologies (OTCBB: UVFT) Announces Growth of National Distributor Network for UV-400 Bacteria Killing Air Purifier
Investorideas.com - Biotech Stocks Update; UV Flu Technologies (OTCBB: UVFT) Announces Growth of National Distributor Network for UV-400 Bacteria Killing Air Purifier
Specialty Distributors Significantly Increase Target Market Penetration
CENTERVILLE, MA – November 2, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce the recent signing of agreements with 3 new distributors to commence offering the ViraTech UV-400 to their market segment commercial accounts.
The new distributors include Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area.
"These agreements represent the beginning of our national initiative to add key representatives and distributors to cover our 5 primary target markets and segments. We identify those markets in no particular order as: Hospitality, including hotels, casinos, and spas; Medical, including hospitals, medical offices and nursing homes; the Government sector, which includes a huge inventory of installations, schools, Indian reservations and government offices; Athletics, including health clubs and sports teams; and Volatile Organic Compound (VOC) locations, which include many salons, laboratories and funeral homes," said Jack Lennon, President of UV Flu.
Mr. Lennon continues, "These new distributors have existing relationships in their respective segments, and are all actively diversifying their reach. As an example, we have been advised that just this week UV Air added Tactical Office Solutions in Woburn, MA to their client list. Tactical is an organization owned and operated by a disabled service veteran, and works exclusively within the government sector. With this in mind, UV Flu has begun all appropriate steps towards full eligibility under government procurement processes. With the addition of our new distributors, the Company is confident it will be announcing national accounts, including government contracts in the near future."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/
Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Specialty Distributors Significantly Increase Target Market Penetration
CENTERVILLE, MA – November 2, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce the recent signing of agreements with 3 new distributors to commence offering the ViraTech UV-400 to their market segment commercial accounts.
The new distributors include Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area.
"These agreements represent the beginning of our national initiative to add key representatives and distributors to cover our 5 primary target markets and segments. We identify those markets in no particular order as: Hospitality, including hotels, casinos, and spas; Medical, including hospitals, medical offices and nursing homes; the Government sector, which includes a huge inventory of installations, schools, Indian reservations and government offices; Athletics, including health clubs and sports teams; and Volatile Organic Compound (VOC) locations, which include many salons, laboratories and funeral homes," said Jack Lennon, President of UV Flu.
Mr. Lennon continues, "These new distributors have existing relationships in their respective segments, and are all actively diversifying their reach. As an example, we have been advised that just this week UV Air added Tactical Office Solutions in Woburn, MA to their client list. Tactical is an organization owned and operated by a disabled service veteran, and works exclusively within the government sector. With this in mind, UV Flu has begun all appropriate steps towards full eligibility under government procurement processes. With the addition of our new distributors, the Company is confident it will be announcing national accounts, including government contracts in the near future."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/
Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Monday, November 1, 2010
Investorideas.com - Featured Biotech/Pharma Stock Profile Update for Biotech Investors; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Investorideas.com - Featured Biotech/Pharma Stock Profile Update for Biotech Investors; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Recent Key Highlights; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Visit this company: www.biosantepharma.com
Point Roberts, WA, LINCOLNSHIRE, Ill - November 1, 2010 (Investorideas.com newswire, www.biotechindustrystocks.com) updates the showcase biotech stock profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports recent news; "BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation."
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration(FDA) Special Protocol Assessment and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in PhaseII clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction (FSD) potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products is over $20 billion.
BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of FSD. LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. To date, over 2,500 women have been enrolled in the safety study. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians for women in 2009.
BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma.
BioSante is focused primarily on LibiGel, however, the Company also is seeking future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myloid leukemia and chronic myeloid leukemia vaccines.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
"LINCOLNSHIRE , Illinois (October 25, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product."
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Financial Highlights
At September 30, 2010, BioSante had approximately $36M in cash
Monthly burn rate of approximately $3.5M
Investment Highlights
Financial resources to implement plan
Late stage pharmaceutical product portfolio with significant growth potential
LibiGel in three ongoing Phase III safety and efficacy clinical studies
Elestrin is FDA approved and marketed in the U.S.
Proprietary cancer vaccines in Phase II clinical trials
Focused growth strategy
Management's proven ability to gain FDA approval, implement plans and increase stockholder value
Key Products
LibiGel® - In development under an SPA for treatment of female sexual dysfunction. Three Phase III safety and efficacy clinical studies are ongoing.
ElestrinTM - FDA approved transdermal gel for treatment of hot flashes; currently marketed in the U.S. by Azur Pharma.
The Pill-PlusTM - Triple hormone contraceptive in Phase II clinical development combining hormone contraceptive and androgen. Licensed to and being developed by Pantarhei Bioscience for oral uses.
Bio-T-GelTM - In development by TEVA USA for the treatment of hypogonadism in men.
Cancer Vaccines - A portfolio of cancer vaccines in Phase II clinical trials for various cancer types, conducted at Johns Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks800 665 0411 cvanzant@investorideas.com
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Recent Key Highlights; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Visit this company: www.biosantepharma.com
Point Roberts, WA, LINCOLNSHIRE, Ill - November 1, 2010 (Investorideas.com newswire, www.biotechindustrystocks.com) updates the showcase biotech stock profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports recent news; "BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation."
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration(FDA) Special Protocol Assessment and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in PhaseII clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction (FSD) potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products is over $20 billion.
BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of FSD. LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. To date, over 2,500 women have been enrolled in the safety study. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians for women in 2009.
BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma.
BioSante is focused primarily on LibiGel, however, the Company also is seeking future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myloid leukemia and chronic myeloid leukemia vaccines.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
"LINCOLNSHIRE , Illinois (October 25, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product."
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Financial Highlights
At September 30, 2010, BioSante had approximately $36M in cash
Monthly burn rate of approximately $3.5M
Investment Highlights
Financial resources to implement plan
Late stage pharmaceutical product portfolio with significant growth potential
LibiGel in three ongoing Phase III safety and efficacy clinical studies
Elestrin is FDA approved and marketed in the U.S.
Proprietary cancer vaccines in Phase II clinical trials
Focused growth strategy
Management's proven ability to gain FDA approval, implement plans and increase stockholder value
Key Products
LibiGel® - In development under an SPA for treatment of female sexual dysfunction. Three Phase III safety and efficacy clinical studies are ongoing.
ElestrinTM - FDA approved transdermal gel for treatment of hot flashes; currently marketed in the U.S. by Azur Pharma.
The Pill-PlusTM - Triple hormone contraceptive in Phase II clinical development combining hormone contraceptive and androgen. Licensed to and being developed by Pantarhei Bioscience for oral uses.
Bio-T-GelTM - In development by TEVA USA for the treatment of hypogonadism in men.
Cancer Vaccines - A portfolio of cancer vaccines in Phase II clinical trials for various cancer types, conducted at Johns Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks800 665 0411 cvanzant@investorideas.com
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Thursday, October 28, 2010
Investorideas.com - Biotech /Pharma Market Movers; (NYSE:BSX), (NASDAQ:BPAX), (OTCBB: UVFT), (NASDAQ: CELG) Stocks to Watch
Investorideas.com - Biotech /Pharma Market Movers; (NYSE:BSX), (NASDAQ:BPAX), (OTCBB: UVFT), (NASDAQ: CELG) Stocks to Watch
Boston Scientific (NYSE:BSX) Agrees to Sell Neurovascular Business to Stryker; StockTrades Over 16 Millions Shares in Morning Trading
Point Roberts, WA –October 28, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot of Market Gainers for today’s trading.. Bullish trading in some of the stocks includes Boston Scientific Corporation. (NSYE: BSX), one of the top advancing stocks on the NYSE currently trading at 6.3220, up 0.0120 (0.19%) on over 16 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release October 28th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.54, up 0.01 (0.65%)
Boston Scientific Corporation. (NYSE:BSX) trading at $6.3220, up 0.0120 (0.19%)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.31 on over 500,000 shares in volume
Celgene Corporation (NASDAQ: CELG) trading at $61.52, up 2.11 (3.55%)
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
Boston Scientific Corporation. (NYSE:BSX)
Recent News; Boston Scientific Agrees to Sell Neurovascular Business to Stryker
“Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months. The Company expects to record a gain upon closing in excess of $500 million, excluding any impact of the receipt of future milestone payments. Total after-tax proceeds, assuming the achievement of these milestones, are expected to be approximately $1.2 billion. The Company expects to allocate approximately half of the net proceeds to acquisitions and the remainder to the retirement of pre-payable debt. The transaction is expected to close before the end of the year, subject to receipt of regulatory clearances and satisfaction of other customary conditions. As a result of the divestiture, the Company expects 2011 earnings per share to be diluted by approximately four to six cents on both a GAAP and adjusted basis.”
Full Article: http://finance.yahoo.com/news/Boston-Scientific-Agrees-to-prnews-3242744555.html?x=0&.v=1
About Boston Scientific Corporation. (NYSE:BSX): Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Boston Scientific (NYSE:BSX) Agrees to Sell Neurovascular Business to Stryker; StockTrades Over 16 Millions Shares in Morning Trading
Point Roberts, WA –October 28, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot of Market Gainers for today’s trading.. Bullish trading in some of the stocks includes Boston Scientific Corporation. (NSYE: BSX), one of the top advancing stocks on the NYSE currently trading at 6.3220, up 0.0120 (0.19%) on over 16 million shares.
Biotech /Pharma Sector Trading Snapshot: (as of time of release October 28th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.54, up 0.01 (0.65%)
Boston Scientific Corporation. (NYSE:BSX) trading at $6.3220, up 0.0120 (0.19%)
UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.31 on over 500,000 shares in volume
Celgene Corporation (NASDAQ: CELG) trading at $61.52, up 2.11 (3.55%)
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
Boston Scientific Corporation. (NYSE:BSX)
Recent News; Boston Scientific Agrees to Sell Neurovascular Business to Stryker
“Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months. The Company expects to record a gain upon closing in excess of $500 million, excluding any impact of the receipt of future milestone payments. Total after-tax proceeds, assuming the achievement of these milestones, are expected to be approximately $1.2 billion. The Company expects to allocate approximately half of the net proceeds to acquisitions and the remainder to the retirement of pre-payable debt. The transaction is expected to close before the end of the year, subject to receipt of regulatory clearances and satisfaction of other customary conditions. As a result of the divestiture, the Company expects 2011 earnings per share to be diluted by approximately four to six cents on both a GAAP and adjusted basis.”
Full Article: http://finance.yahoo.com/news/Boston-Scientific-Agrees-to-prnews-3242744555.html?x=0&.v=1
About Boston Scientific Corporation. (NYSE:BSX): Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Wednesday, October 27, 2010
Investorideas.com - Direct to Consumer Company, YesDTC (OTCBB: YESD.PK) Announces Infomercial for the MediPendant(TM) Medical Alarm, Airing on Six National Cable Stations
Investorideas.com - Direct to Consumer Company, YesDTC (OTCBB: YESD.PK) Announces Infomercial for the MediPendant(TM) Medical Alarm, Airing on Six National Cable Stations
Visit this company: www.yesdtc.com
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) - Retail/ Consumer Stock News - YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, reports today it will officially begin airing its new infomercial for the MediPendant(TM) personal medial alarm, by Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), beginning today on six national cable stations in addition to local broadcast stations.
The new infomercial for MediPendant(TM) is sponsored by YesDTC and is set to start airing on Wednesday October 27th on the Discovery Health channel. It will continue to run throughout the week at various times on multiple national cable stations including Discovery Health, ESPN News, Inspiration, Lifetime Movie, Tru TV and TV Land as well as on local broadcast stations such as Northwest Cable News, until the end of the month.
Following the successful conclusion of this test market run, YesDTC plans to expand programming of the infomercial nationwide in a full rollout of the MediPendant(TM) marketing campaign. The campaign will target a wide audience of viewers in the 30 to 55 year age range who have elderly parents or loved ones that could benefit from the safety and assurance the MediPendant(TM) device can provide, including access to medical and emergency response personnel and/or personal contacts within the device user's network of friends and family.
The MediPendant(TM) infomercial can also be viewed by clicking on the following link: http://vimeo.com/16188152.
About the MediPendant(TM) Personal Alarm Device
Medical Alarm Concepts(TM) offers a unique, patented, medical emergency alarm system that is different from all other personal emergency response (PERS) systems on the market today. MDHI's MediPendant(TM) product offers several revolutionary and highly desirable features, including the ability to speak and listen to the operator directly through the pendant, an extended range of mobility from the base station, which enables the user to move virtually anywhere in or around their home, and a call center staffed around the clock with EMT-certified operators. Specifically, the MediPendant(TM) system enables the device wearer to move up to 600+ feet away from the main base station, a distance that far exceeds competitive offerings on the market today that instead require the user to be within speaking distance of the base station box, a situation that may not be conducive to an emergency if the end user is not near the base station.
Additionally, MediPendant's(TM) advanced call center technology allows for three-way calling between the operator, the user, and the dispatched first responders and/or a friend and family member. Currently, no other available PERS systems offer the benefit of three-way voice conferencing directly through the pendant. Finally, EMT-certified operators are guaranteed to stay on the line with the MediPendant(TM) user until the problem is resolved or help arrives.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, IncChristian Kirsebom(925) 247-6666
Visit the YESD showcase profile at Investorideas.com Request News and Info on YESD Disclosure, Disclaimer/
YESD is a paid advertising client on Investorideas.com. YESD: one time fee five thousand and thirty thousand in shares
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Visit this company: www.yesdtc.com
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) - Retail/ Consumer Stock News - YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, reports today it will officially begin airing its new infomercial for the MediPendant(TM) personal medial alarm, by Medical Alarm Concepts Holding, Inc. (OTCBB:MDHI), beginning today on six national cable stations in addition to local broadcast stations.
The new infomercial for MediPendant(TM) is sponsored by YesDTC and is set to start airing on Wednesday October 27th on the Discovery Health channel. It will continue to run throughout the week at various times on multiple national cable stations including Discovery Health, ESPN News, Inspiration, Lifetime Movie, Tru TV and TV Land as well as on local broadcast stations such as Northwest Cable News, until the end of the month.
Following the successful conclusion of this test market run, YesDTC plans to expand programming of the infomercial nationwide in a full rollout of the MediPendant(TM) marketing campaign. The campaign will target a wide audience of viewers in the 30 to 55 year age range who have elderly parents or loved ones that could benefit from the safety and assurance the MediPendant(TM) device can provide, including access to medical and emergency response personnel and/or personal contacts within the device user's network of friends and family.
The MediPendant(TM) infomercial can also be viewed by clicking on the following link: http://vimeo.com/16188152.
About the MediPendant(TM) Personal Alarm Device
Medical Alarm Concepts(TM) offers a unique, patented, medical emergency alarm system that is different from all other personal emergency response (PERS) systems on the market today. MDHI's MediPendant(TM) product offers several revolutionary and highly desirable features, including the ability to speak and listen to the operator directly through the pendant, an extended range of mobility from the base station, which enables the user to move virtually anywhere in or around their home, and a call center staffed around the clock with EMT-certified operators. Specifically, the MediPendant(TM) system enables the device wearer to move up to 600+ feet away from the main base station, a distance that far exceeds competitive offerings on the market today that instead require the user to be within speaking distance of the base station box, a situation that may not be conducive to an emergency if the end user is not near the base station.
Additionally, MediPendant's(TM) advanced call center technology allows for three-way calling between the operator, the user, and the dispatched first responders and/or a friend and family member. Currently, no other available PERS systems offer the benefit of three-way voice conferencing directly through the pendant. Finally, EMT-certified operators are guaranteed to stay on the line with the MediPendant(TM) user until the problem is resolved or help arrives.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, IncChristian Kirsebom(925) 247-6666
Visit the YESD showcase profile at Investorideas.com Request News and Info on YESD Disclosure, Disclaimer/
YESD is a paid advertising client on Investorideas.com. YESD: one time fee five thousand and thirty thousand in shares
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Direct to Consumer Medical/ Biotech Stocks; YesDTC (OTCBB: YESD.PK), GENEREX BIOTECH CORP (GNBT.PK), Utah Medical Products, Inc. (NASDAQ:UTMD)
Investorideas.com - Direct to Consumer Medical/ Biotech Stocks; YesDTC (OTCBB: YESD.PK), GENEREX BIOTECH CORP (GNBT.PK), Utah Medical Products, Inc. (NASDAQ:UTMD)
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) – Investorideas.com, a leader in sector investor research including biotech and medical stocks, reports on recent news and developments from YesDTC (OTCBB: YESD.PK) and GENEREX BIOTECH CORP (GNBT.PK) and Utah Medical Products, Inc. (NASDAQ:UTMD).
Recent news:
YesDTC (OTCBB: YESD.PK) News:
YesDTC (OTCBB: YESD.PK) Announces the Initial Airing of a New Infomercial for the MediPendant(TM) Medical Alarm
YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, announced today the Company and its product partner, Medical Alarms Concepts Holding, Inc. (OTCBB:MDHI), will begin airing a new infomercial via direct response television (DRTV) for the innovative and technologically superior MediPendant(TM) medical alarm device. The airing of the infomercial marks the commencement of a new DRTV marketing campaign designed to target a wide reaching national audience.
Full News: http://www.investorideas.com/CO/YESD/news/10261.asp
GENEREX BIOTECH CORP (GNBT.PK) News:
Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
GMD's expertise in governmental & insurer reimbursement expected to be a valuable asset for Generex's diabetes platform
WORCESTER, Mass., Oct. 11 /-- Generex Biotechnology Corporation (NasdaqCM: GNBT) (www.generex.com) today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC ("GMD") of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications (www.globalmeddirect.com).
Full news see company website.
Note Generex Biotechnology Corporation (NasdaqCM: GNBT) is now trading under stock symbol
(GNBT.PK).
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2010
SALT LAKE CITY, Oct. 21, 2010 - Utah Medical Products, Inc. (Nasdaq:UTMD - News) reports lower sales, improved profit margins and a stronger ending balance sheet for the third calendar quarter (3Q) 2010 compared to 3Q 2009.
Full news : http://finance.yahoo.com/news/Utah-Medical-Products-Inc-pz-1621271546.html?x=0&.v=1
Utah Medical markets its products through direct sales representatives, independent manufacturers representatives, specialty distributors, national hospital distribution companies, and other medical device manufacturers in the United States; and through other medical device companies and independent medical products distributors internationally
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee five thousand and thirty thousand in shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
SAN FRANCISCO - October 27, 2010 (Investorideas.com newswire) – Investorideas.com, a leader in sector investor research including biotech and medical stocks, reports on recent news and developments from YesDTC (OTCBB: YESD.PK) and GENEREX BIOTECH CORP (GNBT.PK) and Utah Medical Products, Inc. (NASDAQ:UTMD).
Recent news:
YesDTC (OTCBB: YESD.PK) News:
YesDTC (OTCBB: YESD.PK) Announces the Initial Airing of a New Infomercial for the MediPendant(TM) Medical Alarm
YesDTC Holdings, Inc. (OTCBB:YESD.PK), a direct-to-consumer global distributor and marketer of consumer goods and products, announced today the Company and its product partner, Medical Alarms Concepts Holding, Inc. (OTCBB:MDHI), will begin airing a new infomercial via direct response television (DRTV) for the innovative and technologically superior MediPendant(TM) medical alarm device. The airing of the infomercial marks the commencement of a new DRTV marketing campaign designed to target a wide reaching national audience.
Full News: http://www.investorideas.com/CO/YESD/news/10261.asp
GENEREX BIOTECH CORP (GNBT.PK) News:
Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
GMD's expertise in governmental & insurer reimbursement expected to be a valuable asset for Generex's diabetes platform
WORCESTER, Mass., Oct. 11 /-- Generex Biotechnology Corporation (NasdaqCM: GNBT) (www.generex.com) today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC ("GMD") of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications (www.globalmeddirect.com).
Full news see company website.
Note Generex Biotechnology Corporation (NasdaqCM: GNBT) is now trading under stock symbol
(GNBT.PK).
Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2010
SALT LAKE CITY, Oct. 21, 2010 - Utah Medical Products, Inc. (Nasdaq:UTMD - News) reports lower sales, improved profit margins and a stronger ending balance sheet for the third calendar quarter (3Q) 2010 compared to 3Q 2009.
Full news : http://finance.yahoo.com/news/Utah-Medical-Products-Inc-pz-1621271546.html?x=0&.v=1
Utah Medical markets its products through direct sales representatives, independent manufacturers representatives, specialty distributors, national hospital distribution companies, and other medical device manufacturers in the United States; and through other medical device companies and independent medical products distributors internationally
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Contact:
YesDTC Holdings, Inc
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee five thousand and thirty thousand in shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Investorideas.com - Biotech/Pharma Sector Trading Snapshot; (NASDAQ: BPAX), (NASDAQ: CADX), (NASDAQ:SUPG), (OTCBB: UVFT)
Investorideas.com - Biotech/Pharma Sector Trading Snapshot; (NASDAQ: BPAX), (NASDAQ: CADX), (NASDAQ:SUPG), (OTCBB: UVFT)
Point Roberts, WA –October 27, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot, as of the close October 26th. Bullish trading in some of the stocks included SuperGen, Inc.(NasdaqGM: SUPG), one of the top advancing stocks on the NASDAQ, closing at $2.82, up $ 0.49 (21.03%), followed by additional gains in after market trading.
Biotech /Pharma Sector Trading Snapshot: (as of close October 26th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed at $1.57, up 0.01 (0.64%), trading as high as $1.59 on the day.
Cadence Pharmaceuticals Inc. (NASDAQ: CADX) closed at $8.9, up 0.24 (2.75%) on 445,648 shares.
SuperGen Inc. (NASDAQ:SUPG) closed at $2.82, up $ 0.49 (21.03%) on over 3.4 million shares.
UV Flu Technologies, Inc. (OTCBB: UVFT) closed at $0.3850, up 0.0250 (6.94%) on over 1.3 million shares.
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
SuperGen, Inc. (NASDAQ:SUPG) News:
SuperGen Reports 2010 Third Quarter Financial Results
Dacogen Royalty Revenue Increases 28% from Same Prior Year Quarter Increases Annual Royalty and Net Income Guidance for 2010
DUBLIN, Calif.—October 25, 2010 - SuperGen, Inc. (NASDAQ:SUPG ) today reported financial results for the third quarter and nine months ended September 30, 2010.
“The third quarter was another profitable one for SuperGen. Royalties from Dacogen sales increased significantly, and we ended the quarter with more than $112 million in unrestricted cash, cash equivalents and current and non-current marketable securities, and no debt. As a result, we have raised both our royalty revenue and net income guidance for 2010,” said James S.J. Manuso, Ph.D., President and CEO. “We continue to advance the development of our drugs in the clinic, and SGI-110, a novel, second-generation DNA methylation inhibitor, is on schedule to enter a first-in-human clinical trial in myelodysplastic syndromes and AML during November.”
Full News; http://finance.yahoo.com/news/SuperGen-Reports-2010-Third-bw-1951926175.html?x=0&.v=1
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA –October 27, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot, as of the close October 26th. Bullish trading in some of the stocks included SuperGen, Inc.(NasdaqGM: SUPG), one of the top advancing stocks on the NASDAQ, closing at $2.82, up $ 0.49 (21.03%), followed by additional gains in after market trading.
Biotech /Pharma Sector Trading Snapshot: (as of close October 26th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed at $1.57, up 0.01 (0.64%), trading as high as $1.59 on the day.
Cadence Pharmaceuticals Inc. (NASDAQ: CADX) closed at $8.9, up 0.24 (2.75%) on 445,648 shares.
SuperGen Inc. (NASDAQ:SUPG) closed at $2.82, up $ 0.49 (21.03%) on over 3.4 million shares.
UV Flu Technologies, Inc. (OTCBB: UVFT) closed at $0.3850, up 0.0250 (6.94%) on over 1.3 million shares.
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
SuperGen, Inc. (NASDAQ:SUPG) News:
SuperGen Reports 2010 Third Quarter Financial Results
Dacogen Royalty Revenue Increases 28% from Same Prior Year Quarter Increases Annual Royalty and Net Income Guidance for 2010
DUBLIN, Calif.—October 25, 2010 - SuperGen, Inc. (NASDAQ:SUPG ) today reported financial results for the third quarter and nine months ended September 30, 2010.
“The third quarter was another profitable one for SuperGen. Royalties from Dacogen sales increased significantly, and we ended the quarter with more than $112 million in unrestricted cash, cash equivalents and current and non-current marketable securities, and no debt. As a result, we have raised both our royalty revenue and net income guidance for 2010,” said James S.J. Manuso, Ph.D., President and CEO. “We continue to advance the development of our drugs in the clinic, and SGI-110, a novel, second-generation DNA methylation inhibitor, is on schedule to enter a first-in-human clinical trial in myelodysplastic syndromes and AML during November.”
Full News; http://finance.yahoo.com/news/SuperGen-Reports-2010-Third-bw-1951926175.html?x=0&.v=1
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Investorideas.com - Biotech/Pharma Stock Profile Update; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Investorideas.com - Biotech/Pharma Stock Profile Update; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Recent News; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Point Roberts, WA, LINCOLNSHIRE, Ill –October 27, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) reports the following updates for showcase biotech stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Recent updates to the company profile include company news on its lead near term product LibiGel®, in addition to media kit highlights for investors.
The company reports recent news; “BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation.”
The company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
“LINCOLNSHIRE, Illinois (October 25, 2010) – BioSante Pharmaceuticals, Inc.(NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.”
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. he current market for testosterone and estrogen products is approximately $2.5billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products also is a multi-billion dollar market. BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of female sexual dysfunction (FSD). LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians in 2009. BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma. BioSante will focus primarily on LibiGel, BioSante’s testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The Company also will seek future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia vaccines.
Investment Highlights
• Financial resources to implement plan
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Proprietary CaP technology with aesthetic medicine potential
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and
increase stockholder value
Financial Highlights
• At March 31, 2010, BioSante had approximately $41M in cash
• Monthly burn rate of approximately $2.5-$3.0M
Key Products
LibiGel® — In development under an SPA
for treatment of female sexual dysfunction.
Three Phase III safety and efficacy clinical
studies are ongoing.
ElestrinTM — FDA approved transdermal
gel for treatment of hot flashes; currently
marketed in the U.S. by Azur Pharma.
The Pill-PlusTM — Triple hormone
contraceptive in Phase II clinical development
combining hormone contraceptive and
androgen. Licensed to and being developed
by Pantarhei Bioscience for oral uses.
Cancer Vaccines — A portfolio of
cancer vaccines in Phase II clinical trials for
various cancer types, conducted at Johns
Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Recent News; BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
Point Roberts, WA, LINCOLNSHIRE, Ill –October 27, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) reports the following updates for showcase biotech stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Recent updates to the company profile include company news on its lead near term product LibiGel®, in addition to media kit highlights for investors.
The company reports recent news; “BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation.”
The company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Full Media Kit at: http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
Company Overview:
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies.
Recent Company News:
BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation
“LINCOLNSHIRE, Illinois (October 25, 2010) – BioSante Pharmaceuticals, Inc.(NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.”
Full News: http://www.investorideas.com/CO/BPAX/news/10252.asp
Lead Products – Multi-Billion Dollar Markets
BioSante is focused on developing innovative products for female sexual health and oncology. he current market for testosterone and estrogen products is approximately $2.5billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding more than $2.0 billion. In addition, the current market for hormonal contraception is approximately $3.0 billion. The market for oncology products also is a multi-billion dollar market. BioSante’s lead near term product in development is LibiGel® (testosterone gel) for the treatment of female sexual dysfunction (FSD). LibiGel’s clinical development program consists of two Phase III safety and efficacy trials, being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Each trial will enroll approximately 500 surgically menopausal women for six months of treatment in double-blind placebo-controlled trials. Also ongoing is one Phase III cardiovascular events-driven safety study, enrolling between 2,500 and 4,000 women with cardiovascular risk factors, on therapy for one year and then followed for an additional four years after New Drug Application (NDA) submission and potential FDA approval. A completed LibiGel Phase II clinical trial has shown excellent results with a significant 238% increase in the total number of satisfying sexual events. There are currently no pharmaceutical products approved for the treatment of FSD in the U.S. however over 4 million prescriptions for testosterone were written off-label by physicians in 2009. BioSante’s marketed product, ElestrinTM, is FDA approved to reduce hot flashes in menopausal women. The lower of the two approved Elestrin doses is 67% lower than the lowest dose transdermal patch available for the treatment of hot flashes. Elestrin is marketed in the U.S. by Azur Pharma. BioSante will focus primarily on LibiGel, BioSante’s testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The Company also will seek future development opportunities for its cancer vaccines, which are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Currently, several of BioSante’s cancer immunotherapies are in Phase II clinical trials at Johns Hopkins Cancer Center and BioSante has been granted FDA Orphan Drug designation for its pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia vaccines.
Investment Highlights
• Financial resources to implement plan
• Late stage pharmaceutical product portfolio with significant growth potential
• LibiGel in three ongoing Phase III safety and efficacy clinical studies
• Elestrin is FDA approved and marketed in the U.S.
• Proprietary cancer vaccines in Phase II clinical trials
• Proprietary CaP technology with aesthetic medicine potential
• Focused growth strategy
• Management’s proven ability to gain FDA approval, implement plans and
increase stockholder value
Financial Highlights
• At March 31, 2010, BioSante had approximately $41M in cash
• Monthly burn rate of approximately $2.5-$3.0M
Key Products
LibiGel® — In development under an SPA
for treatment of female sexual dysfunction.
Three Phase III safety and efficacy clinical
studies are ongoing.
ElestrinTM — FDA approved transdermal
gel for treatment of hot flashes; currently
marketed in the U.S. by Azur Pharma.
The Pill-PlusTM — Triple hormone
contraceptive in Phase II clinical development
combining hormone contraceptive and
androgen. Licensed to and being developed
by Pantarhei Bioscience for oral uses.
Cancer Vaccines — A portfolio of
cancer vaccines in Phase II clinical trials for
various cancer types, conducted at Johns
Hopkins Cancer Center.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com. (three thousand per month)
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante
Investorideas.com - Biotech Stocks Update; UV Flu Technologies (OTCBB: UVFT) Signs LOI to Acquire Leading Manufacturer of Industrial Grade Air Purification Systems
Investorideas.com - Biotech Stocks Update; UV Flu Technologies (OTCBB: UVFT) Signs LOI to Acquire Leading Manufacturer of Industrial Grade Air Purification Systems
Visit this company: www.uvflutech.com
CENTERVILLE, MA – October 27, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a Letter of Intent ("LOI") to acquire 100% of the ownership of a major US manufacturer of high quality air purification equipment designed for industrial applications and specializing in the medical and hospitality marketplace.
The agreement includes a patented, trademarked product line, with dozens of national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The company's sales include an installed base of several thousand units in over 1000 unique facilities nationwide.
The transaction will use commercially reasonable efforts to execute a definitive merger agreement by mid-November and the Definitive Agreement shall contain customary representation and warranties, covenants and indemnification provisions. By mutual agreement, the name of the selling company will be withheld until the close of the transaction.
"This is an excellent and timely acquisition for UV Flu," said Jack Lennon, President of UV Flu Technologies. "The company we are acquiring makes some of the finest, hi-end, air purification equipment available anywhere. Their highest volume product is patented, trade-marked, and is based on HEPA equipment which also combines UV germicidal technology designed to capture 99.97% of the particulates passing through the system. It complements and extends our existing technology and capabilities by dramatically increasing filtration protection throughout much larger spaces, particularly in areas where smoke and dust play a major role. Construction sites, casinos, smoking lounges and restaurants are significant users of the product line, including over 400 hospitals that rely on its particulate trapping abilities to clean the air of harmful pathogens. This high grade HEPA based technology is best suited to industrial/commercial environments which incorporate designated maintenance schedules and generally includes service contracts as opposed to residential or small commercial settings, where stand-alone HEPA users may neglect to change the filters in a timely manner thereby compromising the effectiveness of their systems."
"The acquisition will be operated as a subsidiary of UV Flu Technologies, and will provide a US manufacturing base to aid in the pursuit of government and DoD contract opportunities. We hope this added market segment will also lead to additional jobs and overall growth for the Company," said Mr. Lennon. "The enhanced product line will make us increasingly attractive to large US distributors, and increase our visibility within the hospital, hotel and casino marketplace. Upon the close of the transaction we will immediately introduce our distributors to the entire product line, both domestically, as well as internationally. We believe the synergies will be extraordinary and hope to dramatically increase our revenue estimates for 2011 as a result. Once our residential model is introduced to the lineup in 2011 we are highly optimistic for significant traction across the entire segment. We are excited by the prospects and look forward to offering a full line of products that really work; all with verified and laboratory proven test data for every application."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Visit this company: www.uvflutech.com
CENTERVILLE, MA – October 27, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a Letter of Intent ("LOI") to acquire 100% of the ownership of a major US manufacturer of high quality air purification equipment designed for industrial applications and specializing in the medical and hospitality marketplace.
The agreement includes a patented, trademarked product line, with dozens of national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The company's sales include an installed base of several thousand units in over 1000 unique facilities nationwide.
The transaction will use commercially reasonable efforts to execute a definitive merger agreement by mid-November and the Definitive Agreement shall contain customary representation and warranties, covenants and indemnification provisions. By mutual agreement, the name of the selling company will be withheld until the close of the transaction.
"This is an excellent and timely acquisition for UV Flu," said Jack Lennon, President of UV Flu Technologies. "The company we are acquiring makes some of the finest, hi-end, air purification equipment available anywhere. Their highest volume product is patented, trade-marked, and is based on HEPA equipment which also combines UV germicidal technology designed to capture 99.97% of the particulates passing through the system. It complements and extends our existing technology and capabilities by dramatically increasing filtration protection throughout much larger spaces, particularly in areas where smoke and dust play a major role. Construction sites, casinos, smoking lounges and restaurants are significant users of the product line, including over 400 hospitals that rely on its particulate trapping abilities to clean the air of harmful pathogens. This high grade HEPA based technology is best suited to industrial/commercial environments which incorporate designated maintenance schedules and generally includes service contracts as opposed to residential or small commercial settings, where stand-alone HEPA users may neglect to change the filters in a timely manner thereby compromising the effectiveness of their systems."
"The acquisition will be operated as a subsidiary of UV Flu Technologies, and will provide a US manufacturing base to aid in the pursuit of government and DoD contract opportunities. We hope this added market segment will also lead to additional jobs and overall growth for the Company," said Mr. Lennon. "The enhanced product line will make us increasingly attractive to large US distributors, and increase our visibility within the hospital, hotel and casino marketplace. Upon the close of the transaction we will immediately introduce our distributors to the entire product line, both domestically, as well as internationally. We believe the synergies will be extraordinary and hope to dramatically increase our revenue estimates for 2011 as a result. Once our residential model is introduced to the lineup in 2011 we are highly optimistic for significant traction across the entire segment. We are excited by the prospects and look forward to offering a full line of products that really work; all with verified and laboratory proven test data for every application."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Tuesday, October 26, 2010
Investorideas.com - NASDAQ Biotech/Pharma News: BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Positive LibiGel® Data Monitoring Committee Recommendation
Investorideas.com - NASDAQ Biotech/Pharma News: BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Positive LibiGel® Data Monitoring Committee Recommendation
Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
"We are very pleased that the DMC recommended that the study should continue without modification. This means that there are no general or specific safety issues based on their unblinded review of adverse events. The low number of CV events to date is consistent with the safety of testosterone in women," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante. "Once the DMC determines that there are enough subjects enrolled for statistical significance, enrollment of new subjects into the study will be complete. The current LibiGel safety study protocol allows for up to 4,000 women to be enrolled."
Another unblinded statistical analysis will be conducted by the DMC each time there is an additional adjudicated cardiovascular event. With approximately 2,300 women-years of exposure in the study, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, compared to an expected rate of CV events for this study of approximately two percent. Moreover, there have been seven breast cancers reported, a rate of approximately 0.32 percent, compared to an expected rate of approximately 0.35 percent.
Subjects have been in the study for an average of approximately 10.7 months. There are approximately 850 subjects who have been in the study for over one year and approximately 400 subjects who have been in the study for more than two years. The LibiGel Phase III safety study represents the largest data base of the safety of testosterone in women. A new drug application (NDA) can be submitted after an average of 12 months of exposure with subjects followed for five years in total, including after NDA submission and potential FDA approval. BioSante's objective is to submit the LibiGel NDA in 2011.
The statistical analyses of the CV events are based on predefined statistical methods, in accordance with BioSante's agreement with the FDA, to determine if LibiGel can be considered safe for post-menopausal women. Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women.
"With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD," said Stephen M. Simes, BioSante's president & CEO.
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that will enroll between 2,500 and 4,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas
Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
"We are very pleased that the DMC recommended that the study should continue without modification. This means that there are no general or specific safety issues based on their unblinded review of adverse events. The low number of CV events to date is consistent with the safety of testosterone in women," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante. "Once the DMC determines that there are enough subjects enrolled for statistical significance, enrollment of new subjects into the study will be complete. The current LibiGel safety study protocol allows for up to 4,000 women to be enrolled."
Another unblinded statistical analysis will be conducted by the DMC each time there is an additional adjudicated cardiovascular event. With approximately 2,300 women-years of exposure in the study, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, compared to an expected rate of CV events for this study of approximately two percent. Moreover, there have been seven breast cancers reported, a rate of approximately 0.32 percent, compared to an expected rate of approximately 0.35 percent.
Subjects have been in the study for an average of approximately 10.7 months. There are approximately 850 subjects who have been in the study for over one year and approximately 400 subjects who have been in the study for more than two years. The LibiGel Phase III safety study represents the largest data base of the safety of testosterone in women. A new drug application (NDA) can be submitted after an average of 12 months of exposure with subjects followed for five years in total, including after NDA submission and potential FDA approval. BioSante's objective is to submit the LibiGel NDA in 2011.
The statistical analyses of the CV events are based on predefined statistical methods, in accordance with BioSante's agreement with the FDA, to determine if LibiGel can be considered safe for post-menopausal women. Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women.
"With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women, also referred to as FSD," said Stephen M. Simes, BioSante's president & CEO.
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that will enroll between 2,500 and 4,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas
Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Biotech Stock Profile Update; UV Flu Technologies, Inc. (OTCBB: UVFT) New Research Report and New Stock Trading/Chart Video
Investorideas.com - Biotech Stock Profile Update; UV Flu Technologies, Inc. (OTCBB: UVFT) New Research Report and New Stock Trading/Chart Video
Point Roberts, WA –October 26, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) reports the following updates for showcase biotech stock UV Flu Technologies, Inc. (OTCBB: UVFT) Recent updates to the company profile include a new trading /stock Video by www.itsabull.net, in addition to and analyst report by Michael Williams. Michael Williams is America’s top authority on small-cap biotech stock picks.
The company profile is available at http://www.investorideas.com/CO/UVFT/ for interested biotech investors.
UVFT Profile Updates:
UV Flu Technologies Video: http://www.itsallbull.net/iabtv.php?id=424&ref=newsletter
Research Report; MWMarketMovers.com Analyst Report by Michael Williams
Full report at http://www.MWMarketMovers.com
Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting http://www.MWMarketMovers.com With the cold and flu season around the corner, the report highlights how UV Flu Technologies’ innovative products and technologies address indoor air quality issues (where bacteria may be present) by killing airborne bacteria and other contaminants at rates exceeding 99.2% on a first-pass basis. UVFT’s flagship product, the Viratech UV-400 air purification system, has been issued a coveted Class II medical listing from the FDA that enables UV Flu Technologies to market the product as a medical device. Details regarding how UVFT’s technology works are identified within the report. The 12-page color report will be featured in the center of home-delivered copies of tomorrow’s (Wednesday’s) Wall Street Journal. The Wall Street Journal has a total average paid circulation of more than 1.5 million, according to the last Newspaper Publisher’s Statement filed in March 2010 with the Audit Bureau of Circulations. For more information on the company featured in the report, call http://www.uvflutech.com About Michael Williams Market Movers:At Michael Williams Market Movers, we keep our finger on the pulse of change - in commerce, biotech, energy, and digital opportunities way before other investors ever hear about them. To learn more, visit http://www.mwmarketmovers.com .
About UVFT.OB: UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
The research report is the content and opinion of Michael Williams at MWMarketMovers.com and not the opinion of Investorideas.com or related websites.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Point Roberts, WA –October 26, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) reports the following updates for showcase biotech stock UV Flu Technologies, Inc. (OTCBB: UVFT) Recent updates to the company profile include a new trading /stock Video by www.itsabull.net, in addition to and analyst report by Michael Williams. Michael Williams is America’s top authority on small-cap biotech stock picks.
The company profile is available at http://www.investorideas.com/CO/UVFT/ for interested biotech investors.
UVFT Profile Updates:
UV Flu Technologies Video: http://www.itsallbull.net/iabtv.php?id=424&ref=newsletter
Research Report; MWMarketMovers.com Analyst Report by Michael Williams
Full report at http://www.MWMarketMovers.com
Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting http://www.MWMarketMovers.com With the cold and flu season around the corner, the report highlights how UV Flu Technologies’ innovative products and technologies address indoor air quality issues (where bacteria may be present) by killing airborne bacteria and other contaminants at rates exceeding 99.2% on a first-pass basis. UVFT’s flagship product, the Viratech UV-400 air purification system, has been issued a coveted Class II medical listing from the FDA that enables UV Flu Technologies to market the product as a medical device. Details regarding how UVFT’s technology works are identified within the report. The 12-page color report will be featured in the center of home-delivered copies of tomorrow’s (Wednesday’s) Wall Street Journal. The Wall Street Journal has a total average paid circulation of more than 1.5 million, according to the last Newspaper Publisher’s Statement filed in March 2010 with the Audit Bureau of Circulations. For more information on the company featured in the report, call http://www.uvflutech.com About Michael Williams Market Movers:At Michael Williams Market Movers, we keep our finger on the pulse of change - in commerce, biotech, energy, and digital opportunities way before other investors ever hear about them. To learn more, visit http://www.mwmarketmovers.com .
About UVFT.OB: UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
The research report is the content and opinion of Michael Williams at MWMarketMovers.com and not the opinion of Investorideas.com or related websites.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Subscribe to:
Posts (Atom)